1stOncology™: Cancer Intelligence Service – Page 5620 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022

On October 31, 2022 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open (Press release, Concert Pharmaceuticals, OCT 31, 2022, View Source [SID1234622625]). The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call.

An audio-only webcast of the call may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for three months.

Beihai Raises $27 Million to Support Increased Solubility Oncology Drugs

On October 31, 2022 Zhuhai Beihai Biotech reported that it raised $27 million in a Series B Round to develop novel oncology drugs (Press release, Zhuhai Beihai Biotech, OCT 31, 2022, View Source [SID1234622624]). Founded in 2013, Beihai’s lead drug, an innovative docetaxel product, has completed its clinical trials with seven IND approvals in China and the US. The company claims BH009 is the first global candidate built on its insoluble drug solubilization and delivery technology platform. A broad-spectrum antitumor drug, BH009 is indicated for solid tumors. The B round was led by Yikai Venture Capital

CorreGene Closes $14 Million Pre-A+ round for Novel TCR Drugs

On October 31, 2022 Beijing CorreGene Biotechnology reported that it completed $14 million Pre-A+ financing round to develop new cancer drug using its cutting-edge T-cell receptor (TCR-T) platform (Press release, Corregene Biotechnology , OCT 31, 2022, View Source [SID1234622623]). The company says TCR-T can target almost all proteins expressed by tumor cells while CAR-T drugs are limited to targeting antigens expressed on the surface of tumor cells. The platform re-engineers patients’ T cells with optimized TCR. CorreGene has two candidates in early-stage clinical trials. The round was co-led by Riverhead Capital and Xinrui Investment and included Longmen Capital.

Palatin Announces $10 Million Registered Direct Offering

On October 31, 2022 Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, reported that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 1,818,182 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 1,818,182 shares of common stock, at a purchase price of $5.50 per share and accompanying warrant (Press release, Palatin Technologies, OCT 31, 2022, View Source [SID1234622622]). The warrants will be exercisable commencing six months following the issuance date, will expire five and one-half years following the issuance date and have an exercise price of $5.83 per share.

H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

The closing of the offering is expected to occur on or about November 2, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering are expected to be approximately $10 million. Palatin intends to use the net proceeds of this offering for general corporate purposes.

The securities described above are being offered by Palatin pursuant to a shelf registration statement on Form S-3 (File No. 333-262555) that was previously filed with the Securities and Exchange Commission (SEC) on February 7, 2022 and subsequently declared effective on September 26, 2022. The securities are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, when available, may also be obtained by contacting H.C. Wainwright & Co., LLC, at 430 Park Ave., New York, New York 10022, by telephone at (212) 856-5711, or by email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Entry Into a Material Definitive Agreement

On October 31, 2022 Exicure, Inc. (the "Company") reported that entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with CBI USA, Inc. ("CBI USA"), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares (the "Shares") of the Company’s common stock, par value $0.0001 per share (the "Common Stock"), at a purchase price of $1.60 per share (the "Private Placement") (Filing, 8-K, Exicure, OCT 31, 2022, View Source [SID1234622620]). On October 31, 2022, the Company and CBI USA entered into a Side Letter to Securities Purchase Agreement ("Side Letter"), pursuant to which the parties further confirmed and clarified certain agreements between the parties under the Securities Purchase Agreement, including, among other things, CBI USA’s rights to designate a majority of the Board of Directors of the Company immediately after the closing of the Private Placement and CBI USA’s ability to exercise such director designation rights together with its affiliates as a group, provided that such director designation rights are in compliance with Nasdaq Listing Rule 5640.